BELGIUM researchers have found
hay fever medication could help
alleviate symptoms of irritable
bowel syndrome (IBS).
Researches from KU Leuven were
able to identify the link between
IBS sufferer’s hypersensitivity
and the larger quantities of the
substance histamine the patients
carry in their bodies.
KU Leuven gastroenterology
professor Guy Boeckxstaens and his
team have shown histamine has an
impact on the pain receptor TRPV1.
In IBS patients, histamine
released in the gut makes TRPV1
hypersensitive.
A pilot study found patients
who were treated with the
antihistamine ebastine for 12
weeks had significantly less
abdominal pain than the patients
from the control group.
A follow up study will evaluate the
drug on 200 IBS patients.The above article was sent to subscribers in Pharmacy Daily's issue from 15 Jan 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Jan 16
BREAST Cancer Network Australia (BCNA) has welcomed a PBAC recommendation to subsidise the breast cancer drug Enhertu (trastuzumab deruxtecan) for HER2-low metastatic breast cancer on the PBS.
PHARMACY Connect (PC2024) has revealed that Olympian Peter Bol will be sharing his journey from adversity to athletic greatness at the conference in Sep in Sydney.
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.